文献速递脊柱关节炎

比美吉珠单抗治疗中轴型脊柱关节炎与银屑病关节炎的长期安全性更新分析

Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies.
PubMed 文献 · RMD Open · 2026-03-10

基于六项IIb/III期临床研究汇总数据,纳入848例axSpA和1409例PsA患者,比美吉珠单抗160mg每4周给药安全性相似,TEAE发生率axSpA为129.6/100患者年、PsA为126.9/100患者年,未发现新安全性信号。

要点

  • axSpA与PsA的TEAE发生率相似,停药率低
  • 口腔念珠菌感染多为轻中度,严重机会感染罕见
  • 未发现活动性结核,肝事件发生率约5/100患者年

核心结论

  • 比美吉珠单抗在axSpA和PsA患者中耐受性良好,未发现新的安全性信号。

研究设计与样本

  • 汇总六项IIb/III期研究的安全性数据,纳入接受至少一剂比美吉珠单抗160mg每4周的患者。

主要发现

  • 848例axSpA(总暴露2513.8患者年)和1409例PsA(3655.9患者年)被纳入分析。
  • TEAE发生率(EAIR/100患者年)axSpA为129.6,PsA为126.9;因TEAE停药率axSpA为2.4,PsA为2.9。
  • 最常见TEAE为SARS-CoV-2感染(axSpA和PsA均为9.9)、鼻咽炎(axSpA 8.4,PsA 6.8)和上呼吸道感染(axSpA 5.0,PsA 5.7)。
  • 口腔念珠菌感染EAIR/100患者年axSpA为3.5、PsA为3.8,多轻中度,导致停药者axSpA 0.2、PsA 0.3;严重机会感染axSpA 0、PsA 0.1,无活动性结核。
  • 肝事件EAIR/100患者年axSpA为5.3、PsA为5.0;裁决的明确/ probable炎症性肠病、葡萄膜炎、主要不良心血管事件及自杀意念/行为EAIR均低。

临床怎么用

  • 在axSpA和PsA患者中使用比美吉珠单抗时,应关注口腔念珠菌感染和肝事件,但严重感染和机会感染风险低。

局限性

  • 数据截止至2023年7月(III期),随访时间最长5年(III期2年),为汇总分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To present updated integrated safety analyses of bimekizumab in patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA). METHODS: Safety data pooled from six phase IIb/III studies in axSpA and PsA (data-cut: July 2023 for phase III) reported for patients who received ≥1 dose of bimekizumab 160 mg every 4 weeks. Treatment-emergent adverse events (TEAEs) were reported using exposure-adjusted incidence rate per 100 patient-years (EAIR/100 PY). RESULTS: 848 patients with axSpA (total exposure: 2513.8 PY) and 1409 patients with PsA (3655.9 PY) were included. TEAE incidence (EAIR/100 PY) was 129.6 in axSpA and 126.9 in PsA. Study discontinuations due to TEAEs were infrequent (EAIR/100 PY for axSpA: 2.4; PsA: 2.9). The most frequent TEAEs were SARS-CoV-2 (COVID-19) infection (EAIR/100 PY for axSpA: 9.9; PsA: 9.9), nasopharyngitis (EAIR/100 PY for axSpA: 8.4; PsA: 6.8) and upper respiratory tract infection (EAIR/100 PY for axSpA: 5.0; PsA: 5.7). EAIR/100 PY for oral candidiasis was 3.5 in axSpA and 3.8 in PsA; most cases were mild/moderate, with few leading to study discontinuation (EAIR/100 PY for axSpA: 0.2; PsA: 0.3). Serious opportunistic infections were infrequent (EAIR/100 PY for axSpA: 0; PsA: 0.1), with no active tuberculosis. EAIR/100 PY for hepatic events was 5.3 in axSpA and 5.0 in PsA. EAIRs for adjudicated definite/probable inflammatory bowel disease, uveitis, adjudicated major adverse cardiovascular events and adjudicated suicidal ideation/behaviour were low. CONCLUSION: TEAE EAIRs were similar between axSpA and PsA. Bimekizumab demonstrated tolerability up to 5 years (2 years in phase III); no new safety signals were identified. TRIAL REGISTRATION NUMBERS: NCT02963506; NCT03355573; NCT03928704; NCT03928743; NCT04436640; NCT02969525; NCT03347110; NCT03895203; NCT03896581; NCT04009499.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Mease PJ, Merola JF, Magrey M, et al. Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies. RMD Open. 2026. PMID: 41807031. doi:10.1136/rmdopen-2025-006174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。